Edgewise Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	86.1	21.99	15.57	104.92	23.65
Short-Term Investments	232.3	329.95	265.22	24.18	0
Cash & Cash Equivalents	318.39	351.95	280.79	129.09	23.65
Cash Growth	-9.53%	25.34%	117.51%	445.78%	-
Other Current Assets	8.6	5.05	2.98	0.55	0.39
Total Current Assets	327	357	283.77	129.65	24.04
Property, Plant & Equipment	12.69	9.85	0.91	0.52	0.5
Other Long-Term Assets	0.35	0.25	0.55	0.98	0
Total Long-Term Assets	13.04	10.1	1.46	1.49	0.5
Total Assets	340.04	367.1	285.23	131.14	24.54
Accounts Payable	4.03	6.11	3.84	1.58	0.67
Current Debt	0.98	0.61	0	0	0
Other Current Liabilities	11.77	9.87	6.68	2.76	0.47
Total Current Liabilities	16.77	16.59	10.52	4.34	1.13
Long-Term Debt	4.43	3.8	0	0	0
Other Long-Term Liabilities	0	0	0.33	0	40.26
Total Long-Term Liabilities	4.43	3.8	0.33	0	40.26
Total Liabilities	21.21	20.39	10.85	4.34	41.39
Total Debt	5.41	4.41	0	0	0
Debt Growth	22.82%	-	-	-	-
Retained Earnings	-244.76	-144.6	-76.96	-34.15	-17.02
Comprehensive Income	0.1	-1.36	-0.51	0	0
Shareholders' Equity	318.83	346.72	274.38	-33.42	-16.85
Net Cash / Debt	312.98	347.54	280.79	129.09	23.65
Net Cash / Debt Growth	-9.94%	23.77%	117.51%	445.78%	-
Net Cash Per Share	4.91	6.48	7.48	174.69	62.61
Working Capital	310.23	340.41	273.25	125.3	22.91
Book Value Per Share	5.00	6.47	7.31	-45.22	-44.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).